September 19, 2016 — The American Thyroid Association (ATA) will present the John B. Stanbury Thyroid Pathophysiology Medal to Kenneth D. Burman, M.D. at the ATA’s 86th Annual Meeting, September 21-25, 2016, in Denver, Colorado. The John B. Stanbury Thyroid Pathophysiology Medal recognizes outstanding research contributions, either conceptual or technical, to the understanding of thyroid physiology or the pathophysiology of thyroid disease, as evidenced by having a major impact on research or clinical practice related to thyroid diseases.
Dr. Burman is Chief, Endocrine Section at Medstar Washington Hospital Center, Washington, DC. He is a Professor in the Department of Medicine at Georgetown University and Program Director, Integrated Endocrine Fellowship, Georgetown University/Washington Hospital Center. Dr. Burman’s research focus has been in the areas of clinical pathophysiology, autoimmune thyroid disease, and thyroid cancer.
After graduating from Washington University in St. Louis (MO) and receiving his medical degree from the University of Missouri Medical School, Dr. Burman completed a residency in Internal Medicine at Barnes Hospital (Washington University in St. Louis) and an Endocrine Fellowship at Walter Reed Army Medical Center. He remained on the staff at Walter Reed for 22 years before moving to Medstar Washington Hospital Center.
Dr. Burman has published studies investigating the metabolism of thyroid hormone in various clinical states, the role of intrathyroidal lymphocytes in autoimmune thyroid disease, and the mechanism of action and the utility of lithium and cholestyramine in the treatment of Graves’ hyperthyroidism. More recently, he has focused on aspects of thyroid cancer propagation, assessment, and treatment. Dr. Burman has conducted clinical trials designed to identify new agents to treat patients with thyroid cancer. In his clinical research he has also investigated the utility of dosimetry as a method of determining the optimal radioactive iodine dose in the treatment of differentiated thyroid cancer and has performed in vitro studies assessing the repositioning of metformin and nelfinavir in the possible treatment of thyroid cancer.
Dr. Burman has served in various national roles, including as President of the American Thyroid Association, Chair of the FDA Endocrine Advisory Committee, and Deputy Editor, The Journal of Clinical Endocrinology and Metabolism. He is a member of the American Society of Clinical Investigation. Dr. Burman has received multiple awards including the following: The Van Meter Award from the American Thyroid Association for outstanding research by a young investigator; The Paul Starr Award from the American Thyroid Association for outstanding clinical research; and the Overholser Alumni Award for outstanding contributions to medicine from The University of Missouri Medical School. He is a Master in the American College of Physicians (MACP).
###
The American Thyroid Association (ATA) is the leading worldwide organization dedicated to the advancement, understanding, prevention, diagnosis and treatment of thyroid disorders and thyroid cancer. ATA is an international individual membership organization for over 1,700 clinicians and researchers from 43 countries around the world, representing a broad diversity of medical disciplines. It also serves the public, patients and their family through education and awareness efforts.
Celebrating its 93rd anniversary, ATA delivers its mission through several key endeavors: the publication of highly regarded monthly journals, THYROID, Clinical Thyroidology, VideoEndocrinology and Clinical Thyroidology for the Public; annual scientific meetings; biennial clinical and research symposia; research grant programs for young investigators, support of online professional, public and patient educational programs; and the development of guidelines for clinical management of thyroid disease.
More information about ATA is found at www.thyroid.org.